Methadone maintenance therapy versus no opioid The Cochrane Library
... Currently, the major form of medical therapy for heroin dependence internationally involves orally administered methadone. Methadone is an analgesic medication developed to treat pain in the 1940s. It has been, and is still, prescribed widely for the management of pain in America, Australia and Euro ...
... Currently, the major form of medical therapy for heroin dependence internationally involves orally administered methadone. Methadone is an analgesic medication developed to treat pain in the 1940s. It has been, and is still, prescribed widely for the management of pain in America, Australia and Euro ...
CDR Clinical Review Report for Botox (Migraine)
... This report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). Through the Common Drug Review (CDR) process, CADTH undertakes reviews of drug submissions, resubmissions, and requests for advice, and provides formulary listing recommendations to all Canadian publicly f ...
... This report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). Through the Common Drug Review (CDR) process, CADTH undertakes reviews of drug submissions, resubmissions, and requests for advice, and provides formulary listing recommendations to all Canadian publicly f ...
Advanced relief for needle-stick grief
... No overall differences in safety were observed between geriatric subjects and younger subjects. However, increased sensitivity in individual patients greater than 65 years of age cannot be ruled out. After intravenous dosing, the elimination half-life of lidocaine is significantly longer in elderly ...
... No overall differences in safety were observed between geriatric subjects and younger subjects. However, increased sensitivity in individual patients greater than 65 years of age cannot be ruled out. After intravenous dosing, the elimination half-life of lidocaine is significantly longer in elderly ...
FLOVENT HFA (fluticasone propionate) Inhalation Aerosol
... beneficial effects of FLOVENT HFA in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose. A relationship between plasma levels of fluticasone propionate and inhibitory effects on stimulated cortis ...
... beneficial effects of FLOVENT HFA in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose. A relationship between plasma levels of fluticasone propionate and inhibitory effects on stimulated cortis ...
71 PSORIASIS
... the world and varies in severity from minor, localized lesions to complete body coverage, designated erythroderma. Fingernails and toenails are frequently affected (psoriatic nail dystrophy). Psoriasis can also cause inflammation of the joints and adjacent enthesial attachments and has the potential ...
... the world and varies in severity from minor, localized lesions to complete body coverage, designated erythroderma. Fingernails and toenails are frequently affected (psoriatic nail dystrophy). Psoriasis can also cause inflammation of the joints and adjacent enthesial attachments and has the potential ...
FLOVENT HFA (fluticasone propionate) Inhalation
... beneficial effects of FLOVENT HFA in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose. A relationship between plasma levels of fluticasone propionate and inhibitory effects on stimulated cortis ...
... beneficial effects of FLOVENT HFA in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose. A relationship between plasma levels of fluticasone propionate and inhibitory effects on stimulated cortis ...
Randomized, Double-Masked, Sham-Controlled Trial of
... not approved by the U.S. FDA, but was permitted in this study if the investigator deemed PDT to be indicated and the lesion met all of the following criteria: ⱖ 20-letter loss from baseline VA recorded at all study visits over a three-month period that included at least two study visits, total CNV l ...
... not approved by the U.S. FDA, but was permitted in this study if the investigator deemed PDT to be indicated and the lesion met all of the following criteria: ⱖ 20-letter loss from baseline VA recorded at all study visits over a three-month period that included at least two study visits, total CNV l ...
Montelukast versus inhaled corticosteroids in the management of
... MLK. Headache was the most frequent adverse event; in pediatric patients treated for 8 weeks, diarrhoea, laryngitis, pharyngitis, nausea, otitis, sinusitis and viral infections occurred in more than 2% of MLK recipients and were more prevalent in MLK-treated patients than in placebo recipients [5]. ...
... MLK. Headache was the most frequent adverse event; in pediatric patients treated for 8 weeks, diarrhoea, laryngitis, pharyngitis, nausea, otitis, sinusitis and viral infections occurred in more than 2% of MLK recipients and were more prevalent in MLK-treated patients than in placebo recipients [5]. ...
Residential treatment for drug use in Europe - Emcdda
... the nature of treatment and the approaches that may be used — erroneous client expectations about treatment can lead to higher rates of dropout, client perceptions of failure and inefficient use of treatment resources. Although such arguments apply to all forms of treatment, they are particularly re ...
... the nature of treatment and the approaches that may be used — erroneous client expectations about treatment can lead to higher rates of dropout, client perceptions of failure and inefficient use of treatment resources. Although such arguments apply to all forms of treatment, they are particularly re ...
PrCOPAXONE - Teva Canada Innovation
... Reproduction and Teratology). Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. During pre-marketing clinical trials with COPAXONE (20 mg/mL once per day), seven women conceived while being treated with ...
... Reproduction and Teratology). Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. During pre-marketing clinical trials with COPAXONE (20 mg/mL once per day), seven women conceived while being treated with ...
1
... Patients with left ventricular outflow obstruction, (e.g., aortic stenosis and idiopathic hypertrophic subaortic stenosis) can be sensitive to the action of vasodilators, including PDE5 inhibitors. The following groups of patients with cardiovascular disease were not included in clinical safety and ...
... Patients with left ventricular outflow obstruction, (e.g., aortic stenosis and idiopathic hypertrophic subaortic stenosis) can be sensitive to the action of vasodilators, including PDE5 inhibitors. The following groups of patients with cardiovascular disease were not included in clinical safety and ...
AusPAR Tiotropium bromide - Therapeutic Goods Administration
... At the time of this submission the approved indications were COPD: Spiriva Respimat is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary, disease (COPD. Spiriva Respimat is indicated for the prevention of COPD exacerbations. ...
... At the time of this submission the approved indications were COPD: Spiriva Respimat is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary, disease (COPD. Spiriva Respimat is indicated for the prevention of COPD exacerbations. ...
Stroke - Multidisciplinary Association for Psychedelic Studies
... study of the therapeutic use of MDMA in any patient population has yet to be conducted, despite considerable efforts to obtain permission for such studies. Samuel Widmer, MD, Peter Gasser, MD, and other members of the Swiss Medical Society for Psycholytic Therapy received permission from the Swiss M ...
... study of the therapeutic use of MDMA in any patient population has yet to be conducted, despite considerable efforts to obtain permission for such studies. Samuel Widmer, MD, Peter Gasser, MD, and other members of the Swiss Medical Society for Psycholytic Therapy received permission from the Swiss M ...
1-05-b NL 103 - Budesonide Art. 45
... AstraZeneca submitted 22 completed paediatric studies, which were not covered by the EU worksharing project “Assessment of Paediatric data” for the asthma indication, i.e. studies in indications other than asthma, and asthma studies finalised after the Paediatric worksharing submission. In addition ...
... AstraZeneca submitted 22 completed paediatric studies, which were not covered by the EU worksharing project “Assessment of Paediatric data” for the asthma indication, i.e. studies in indications other than asthma, and asthma studies finalised after the Paediatric worksharing submission. In addition ...
Effectiveness of Particle Repositioning Maneuvers in the Treatment
... vertigo (BPPV) is characterized by brief periods of vertigo triggered by a change in the position of a person’s head relative to gravity. In the general population, the lifetime prevalence of BPPV is 2.4%, and the 1-year incidence is 0.6%.1 It is the most common vestibular disorder, accounting for o ...
... vertigo (BPPV) is characterized by brief periods of vertigo triggered by a change in the position of a person’s head relative to gravity. In the general population, the lifetime prevalence of BPPV is 2.4%, and the 1-year incidence is 0.6%.1 It is the most common vestibular disorder, accounting for o ...
Intravascular brachytherapy - Medical Services Advisory Committee
... Cardiovascular disease comprises all diseases and conditions involving the heart and blood vessels, including coronary heart disease, stroke, peripheral vascular disease and heart failure. The main underlying problem in cardiovascular disease is atherosclerosis, the deposition of fat, cholesterol an ...
... Cardiovascular disease comprises all diseases and conditions involving the heart and blood vessels, including coronary heart disease, stroke, peripheral vascular disease and heart failure. The main underlying problem in cardiovascular disease is atherosclerosis, the deposition of fat, cholesterol an ...
A Multi-Center, Randomized, Double Blind, Phase III Trial
... primary endpoint will be GVHD free survival at Day 56 post randomization. Corticosteroids have been used as primary therapy for acute GVHD for many years. Historical published and unpublished data from Johns Hopkins, M. D. Anderson, University of Michigan and others defined an expected 35%-53% compl ...
... primary endpoint will be GVHD free survival at Day 56 post randomization. Corticosteroids have been used as primary therapy for acute GVHD for many years. Historical published and unpublished data from Johns Hopkins, M. D. Anderson, University of Michigan and others defined an expected 35%-53% compl ...
Front-Line therapy in CLL: Assessment of Ibrutinib
... Trial Registration and Randomisation Only authorised members of staff from hospital sites with appropriate trial approvals have permission to register and randomise participants into the trial. 24 hour Registration and Randomisation System - Tel.: 0113 343 2290 or https://lictr.leeds.ac.uk/webrand/ ...
... Trial Registration and Randomisation Only authorised members of staff from hospital sites with appropriate trial approvals have permission to register and randomise participants into the trial. 24 hour Registration and Randomisation System - Tel.: 0113 343 2290 or https://lictr.leeds.ac.uk/webrand/ ...
Protocol S1.
... generally be received within 24 hours (Monday-Friday). Protocol email group: Sites registering to this study should contact the Computer Support Group at the Data Management Center via e-mail [[email protected] for sites in the U.S. (ACTUs) or [email protected] for sites outside the ...
... generally be received within 24 hours (Monday-Friday). Protocol email group: Sites registering to this study should contact the Computer Support Group at the Data Management Center via e-mail [[email protected] for sites in the U.S. (ACTUs) or [email protected] for sites outside the ...
CLINICAL TRIAL FACT SHEET - International Myeloma Foundation
... with Multiple Myeloma Following Autologous Stem Cell Transplant Trial Description: In this phase III study, patients who have had any type of positive response to induction therapy followed by high-dose therapy with stem cell transplant will be randomly assigned by a computer to receive either a pla ...
... with Multiple Myeloma Following Autologous Stem Cell Transplant Trial Description: In this phase III study, patients who have had any type of positive response to induction therapy followed by high-dose therapy with stem cell transplant will be randomly assigned by a computer to receive either a pla ...
Secukinumab - Therapeutic Goods Administration (TGA)
... with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. ...
... with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. ...
effectiveness of homoeopathic similimum treatment
... According to the results obtained from the CFS questionnaire total, the treatment group showed a significant intra-group improvement in the post treatment period, from baseline to both the second (p = 0.001) and third consultations (p=0.002). The placebo group did not show any significant difference ...
... According to the results obtained from the CFS questionnaire total, the treatment group showed a significant intra-group improvement in the post treatment period, from baseline to both the second (p = 0.001) and third consultations (p=0.002). The placebo group did not show any significant difference ...
Otezla - Celgene
... time. An unmet medical need for new treatments remains high, especially for therapies that confer a favorable benefit/risk profile, have alternative mechanisms of action, are convenient to use, and address both the rheumatic and dermatologic manifestations of PsA. Psoriasis is a chronic disease that ...
... time. An unmet medical need for new treatments remains high, especially for therapies that confer a favorable benefit/risk profile, have alternative mechanisms of action, are convenient to use, and address both the rheumatic and dermatologic manifestations of PsA. Psoriasis is a chronic disease that ...
Management of Itch in Atopic Dermatitis
... associated with topical GCs. Topical tacrolimus (Protopic, 0.1% and 0.03% ointment) and topical pimecrolimus (Elidel 1%) are approved by the Food and Drug Administration (FDA) for the treatment of AD. Studies in both adult and pediatric AD patients have demonstrated significantly reduced pruritus wi ...
... associated with topical GCs. Topical tacrolimus (Protopic, 0.1% and 0.03% ointment) and topical pimecrolimus (Elidel 1%) are approved by the Food and Drug Administration (FDA) for the treatment of AD. Studies in both adult and pediatric AD patients have demonstrated significantly reduced pruritus wi ...
Repetitive Transcranial Magnetic Stimulation for the Treatment of
... Researchers have investigated rTMS as an option to treat MDD, as an add-on to drug therapy, and, in particular, as an alternative to electroconvulsive therapy (ECT) for patients with treatment-resistant depression. The advantages of rTMS over ECT for patients with severe refractory depression are th ...
... Researchers have investigated rTMS as an option to treat MDD, as an add-on to drug therapy, and, in particular, as an alternative to electroconvulsive therapy (ECT) for patients with treatment-resistant depression. The advantages of rTMS over ECT for patients with severe refractory depression are th ...
Placebo-controlled study
Placebo-controlled studies are a way of testing a medical therapy in which, in addition to a group of subjects that receives the treatment to be evaluated, a separate control group receives a sham ""placebo"" treatment which is specifically designed to have no real effect. Placebos are most commonly used in blinded trials, where subjects do not know whether they are receiving real or placebo treatment. Often, there is also a further ""natural history"" group that does not receive any treatment at all.The purpose of the placebo group is to account for the placebo effect, that is, effects from treatment that do not depend on the treatment itself. Such factors include knowing one is receiving a treatment, attention from health care professionals, and the expectations of a treatment's effectiveness by those running the research study. Without a placebo group to compare against, it is not possible to know whether the treatment itself had any effect.Patients frequently show improvement even when given a sham or ""fake"" treatment. Such intentionally inert placebo treatments can take many forms, such as a pill containing only sugar, a surgery where nothing efficacious is actually done (just an incision and sometimes some minor touching or handling of the underlying structures), or a medical device (such as an ultrasound machine) that is not actually turned on. Also, due to the body's natural healing ability and statistical effects such as regression to the mean, many patients will get better even when given no treatment at all. Thus, the relevant question when assessing a treatment is not ""does the treatment work?"" but ""does the treatment work better than a placebo treatment, or no treatment at all?"" As one early clinical trial researcher wrote, ""the first object of a therapeutic trial is to discover whether the patients who receive the treatment under investigation are cured more rapidly, more completely or more frequently, than they would have been without it.""p.195 More broadly, the aim of a clinical trial is to determine what treatments, delivered in what circumstances, to which patients, in what conditions, are the most effective.Therefore, the use of placebos is a standard control component of most clinical trials, which attempt to make some sort of quantitative assessment of the efficacy of medicinal drugs or treatments. Such a test or clinical trial is called a placebo-controlled study, and its control is of the negative type. A study whose control is a previously tested treatment, rather than no treatment, is called a positive-control study, because its control is of the positive type.Government regulatory agencies approve new drugs only after tests establish not only that patients respond to them, but also that their effect is greater than that of a placebo (by way of affecting more patients, by affecting responders more strongly, or both). As a result, ""placebo-controlled studies often are designed in such a way that disadvantages the placebo condition"".